The Myo-P®: A Patented Modular Living Implant Platform for the CNS
OUR TECHOLOGY
IMMORTALISED HUMAN MYOBLAST CELLS
Low-immunogenicity human myogenic cells engineered for long-term survival in the metabolically restrictive CNS and sustained secretion of potent, disease-specific therapeutic proteins.
MYO-POD®
Ultra-compact 23 × 1.2 mm biocompatible hollow-fibre cell macroencapsulation implant enabling selective bidirectional diffusion of molecules and minimally invasive implantation and retrieval.
SUSTAINED PROTEIN DELIVERY BEYOND THE BBB
Designed to enable sustained CNS protein delivery, with the potential to reduce repeat administration burden, peak-to-trough fluctuation and off-target toxicities.
MINIMALLY INVASIVE IMPLANTATION & RETRIEVAL
Designed for long-term implantation using a minimally invasive neurosurgical approach established in clinical practice, with retrieval and replacement providing a safety fallback.
OFF-THE-SHELF, SCALABLE MANUFACTURING
Bankable immortalised cells combined with a standardised hollow-fibre device enable repeatable, off-the-shelf manufacturing at scale without patient-specific processing.
BUILT FOR BROAD APPLICABILITY
Broad platform applicability, with in vivo proof of concept for myoblasts producing therapeutic enzymes, antibodies, cytokines and antigens, and the Myo-Pod’s ability to encapsulate different cell types.
INNOVATION BENCHMARKS
Translational Readiness and Platform Validation
TRANSLATIONAL CNS VALIDATION
Lead metachromatic leukodystrophy programme developed with the Paris Brain Institute, demonstrating sustained enzyme secretion and good tolerability for at least 5 months following subdural implantation in non-human primates.
INNOSUISSE-BACKED PIPELINE EXPANSION
Second CNS programme in Sanfilippo syndrome type IIIA (MPS IIIA) advancing through an Innosuisse-funded preclinical collaboration with UNIGE, supported by CHF 0.5M in non-dilutive funding.
AWARD-WINNING PHASE I VALIDATION
Phase I evaluation of subcutaneous implantation in personalised cancer immunotherapy, demonstrating favourable safety profile and awarded the 2026 Pfizer Prize for Biomedical Research.
BROAD IP PROTECTION TO 2040
Two patent families protecting the cell platform and cargo-agnostic Myo-Pod® implant, with broad claims across therapeutic areas and granted protection in key markets.
Myo-P4®
Lead programme for metachromatic leukodystrophy (MLD), a rare, fatal genetic neurodegenerative disease principally affecting young children, caused by a deficiency of arylsulfatase A (ARSA). Developed with the Paris Brain Institute, the Myo-P4® is designed to provide sustained CNS delivery of the missing enzyme through an off-the-shelf, retrievable and replaceable implant.
Myo-P5A®
Second programme for Sanfilippo syndrome tyle IIIA (MPS IIIA), a rare genetic neurodegenerative disease affecting young children, caused by a deficiency of sulfamidase (SGSH). Developed with UNIGE under an Innosuisse-funded preclinical programme, the Myo-P5A® is designed for sustained delivery of SGSH to the CNS.